Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The veliparib consisting regimen improved progression-free survival in the overall patient population and among women with BRCA mutation or HRD as compared to chemotherapy
Progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy overall and across prespecified subgroups
Niraparib administered after platinum-based chemotherapy improved progression-free survival in patients with ovarian cancer regardless of BRCA status
Complementary medicines are mostly used by younger patients with better performance status and fewer sites of metastasis
Circulating tumour DNA prior to adjuvant chemotherapy is a marker for disease-free survival in patients with stage III colon cancer
The EPIPHANY index was validated in a prospective PERSEO study
Long-term data from the CheckMate 067 study
Long-term recurrence-free and distant metastasis-free survival favours adjuvant nivolumab over ipilimumab
Systemic treatment based on molecular analysis did not improve survival over empiric chemotherapy in patients with carcinomas of unknown primary site
Two exploratory analysis of the relationship between tissue tumour mutational burden and pembrolizumab efficacy provided conflicting findings
Presentations cover a new classification strategy that may be prognostic of outcome and a new treatment option for leptomeningeal metastases in NSCLC patients
Lung cancer and other thoracic tumours; Anticancer agents and biologic therapy; Personalised medicine
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
